Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice

Pharmacology

Volumn 85, Issue 5, 2010, Pages 286-294

  Kagawa, Yoto ^a   Izawa, Kana ^a   Yano, Haruna ^a   Kamei, Chiaki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Atopic dermatitis; Nerve growth factor; Olopatadine; Prednisolone; Scratching behavior; Skin symptoms

Indexed keywords

CHLORPHENIRAMINE MALEATE; NERVE GROWTH FACTOR; OLOPATADINE; PREDNISOLONE; ALLERGEN; ANTIPRURITIC AGENT; DIBENZOXEPIN DERIVATIVE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; PICRYL CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HAIRLESS MOUSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; SCRATCHING; SKIN; SKIN MANIFESTATION; TREATMENT RESPONSE; ANIMAL; ANIMAL BEHAVIOR; DERMATITIS, ATOPIC; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PRURITUS; SEVERITY OF ILLNESS INDEX; TIME;

ALLERGENS; ANIMALS; ANTIPRURITICS; BEHAVIOR, ANIMAL; DERMATITIS, ATOPIC; DIBENZOXEPINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; MALE; MICE; MICE, HAIRLESS; NERVE GROWTH FACTOR; PICRYL CHLORIDE; PREDNISOLONE; PRURITUS; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS;

EID: 77951953355     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000297508     Document Type: Article

References (31)

1. Wollenberg A, Kraft S, Oppel T, Bieber T: Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol 2000; 25: 530-534.
2. Wahlgren CF: Itch and atopic dermatitis: an overview. J Dermatol 1999; 26: 770-779.
3. Hornstein OP: Guideline for topical treatment in atopic eczema. Handbook of Attopic Eczema 1991: 27-30.
4. Del Rosso J, Friedlander SF: Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005; 53:S50-S58.
5. Cheigh NH: Managing a common disorder in children: atopic dermatitis. J Pediatr Health Care 2003; 17: 84-88.
6. Weston WL, Morelli JG: Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med 2000; 154: 62-64.
7. Tatham A: Atopic dermatitis, cutaneous steroids and cataracts in children: two case reports. J Med Case Reports 2008; 2: 124.
8. Hoare C, Li Wan Po A, Williams H: Systematic review of treatment for atopic eczema. Health Technol Assess 2000; 4: 1-191.
9. Kitagaki H, Fujisawa S, Watanabe K, Hayakawa K, Shiohara T: Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J Invest Dermatol 1995; 105: 749-755.
10. Matsumoto K, Mizukoshi K, Oyobikawa M, Ohshima H, Tagami H: Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. Skin Res Technol 2004; 10: 122-129.
11. Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, Nagai H: Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur J Pharmacol 2002; 448: 175-183.
12. Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, Nagai H: Evaluation and characterization of mouse scratching behavior by a new apparatus, MicroAct. Skin Pharmacol Appl Skin Physiol 2003; 16: 165-175.
13. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW, Ra C: Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997; 9: 461-466.
14. Yamaguchi T, Maekawa T, Nishikawa Y, Nojima H, Kaneko M, Kawakita T, Miyamoto T, Kuraishi Y: Characterization of itch-associated responses of NC mice with mite-induced chronic dermatitis. J Dermatol Sci 2001; 25: 20-28.
15. Ueda Y, Inoue T, Rahman MA, Yatsuzuka R, Jiang S, Kamei C: A new chronic itch model accompanied by skin lesions in hairless mice. Int Immunopharmacol 2006; 6: 1609-1615.
16. Yatsuzuka R, Inoue T, Jiang S, Nakano Y, Kamei C: Development of new atopic dermatitis models characterized by not only itching but also inflammatory skin in mice. Eur J Pharmacol 2007; 565: 225-231.
17. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziski Z: Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002; 205: 40-45.
18. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology 2005; 75: 45-52.
19. Tamura T, Amano T, Ohmori K, Manabe H: The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmacol 2005; 524: 149-154.
20. Cook EB, Stahl JL, Barney NP, Graziano FM: Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000; 5: 471-472.
21. Hayashi K, Kaise T, Ohmori K, Ishii A, Karasawa A: Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly- L -arginine in rats. Jpn J Pharmacol 2001; 87: 167-170.
22. Dou YC, Hagstromer L, Emtestam L, Johansson O: Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study. Arch Dermatol Res 2006; 298: 31-37.
23. Albers KM, Wright DE, Davis BM: Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of the peripheral nervous system. J Neurosci 1994; 14: 1422-1432.
24. Leslie TA, Emson PC, Dowd PM, Woolf CJ: Nerve growth factor contributes to the upregulation of growth-associated protein 43 and preprotachykinin a messenger RNAs in primary sensory neurons following peripheral inflammation. Neuroscience 1995; 67: 753-761.
25. Bennett DL, Koltzenburg M, Priestley JV, Shelton DL, McMahon SB: Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur J Neurosci 1998; 10: 1282-1291.
26. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M: Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002; 147: 71-79.
27. Yamaguchi J, Aihara M, Kobayashi Y, Kambara T, Ikezawa Z: Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci 2009; 53: 48-54.
28. Blasing H, Hendrix S, Paus R: Pro-inflammatory cytokines upregulate the skin immunoreactivity for NGF, NT-3, NT-4 and their receptor, p75NTR in vivo: a preliminary report. Arch Dermatol Res 2005; 296: 580-584.
29. Hattori A, Iwasaki S, Murase K, Tsujimoto M, Sato M, Hayashi K, Kohno M: Tumor necrosis factor is markedly synergistic with interleukin 1 and interferon-gamma in stimulating the production of nerve growth factor in fibroblasts. FEBS Lett 1994; 340: 177-180.
30. Lee SJ, Oh SG, Seo SW, Ahn HJ, Geum D, Cho JJ, Park CS: Oral administration of Astragalus membranaceus inhibits the development of DNFB-induced dermatitis in NC/Nga mice. Biol Pharm Bull 2007; 30: 1468-1471.
31. Iuvone T, Den Bossche RV, D'Acquisto F, Carnuccio R, Herman AG. Evidence that mast cell degranulation, histamine and tumour necrosis factor alpha release occur in LPS-induced plasma leakage in rat skin. Br J Pharmacol 1999; 128: 700-704.